UnitedHealth Group is participating in the COVID-19 Diagnostics Evidence Accelerator — a new public-private partnership that leverages real-world data to enhance COVID-19 response efforts through faster, high-quality, modern scientific research.
Led by the Reagan-Udall Foundation for the Food and Drug Administration, and in collaboration with Friends of Cancer Research, the approximately 50 members of the Diagnostics Evidence Accelerator are meeting weekly to pursue research using real-world data related to COVID-19 test performance, symptoms and presentation, real-time surveillance trends, and immunity. In the process, collaborating organizations will perform their own analyses concurrently and compare results.
“UnitedHealth Group is grateful for the opportunity to be a part of this public-private partnership as we focus on advancing science and practical, real-world research to combat COVID-19,” says Ken Ehlert, chief scientific officer, UnitedHealth Group. “As a member of the Diagnostics Evidence Accelerator, we look forward to making new discoveries that better prevent, detect and intercept this disease to improve the health of individuals and the communities we serve.”
Along with UnitedHealth Group, members of the COVID-19 Diagnostics Evidence Accelerator include government, device manufacturers, technology companies, academic researchers, professional societies, and health systems. Summaries from Diagnostics Evidence Accelerator meetings are posted at EvidenceAccelerator.org.
The Diagnostics Evidence Accelerator builds on the framework and methodologies developed for the COVID-19 Therapeutics Evidence Accelerator launched in April. Initial Evidence Accelerator activities include rapidly finalizing a list of core data elements, identifying critical data to answer high-priority research questions, and establishing uniform analysis parameters.
Learn more about UnitedHealth Group’s scientific research initiatives and our virtual research community at www.unitedinresearch.com.